Clinical trials: Transient Ischaemic Attack
Carotid Artery Diseases, Stroke
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be…
- Conditions
- Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis
- Trial name
- BEACH (NCT00316108)
- Testing
- WALLSTENT® Endoprosthesis™
- Where
- 50 sites in United States
- Volunteers
- 747 people
- Sponsor
- Boston Scientific Corporation
Stroke, Transient Ischemic Attack (TIA)
PROspective Study to OPTimize thE HEALTH of Patients With TIAs (Transient Ischemic Attacks) and Stroke Admitted to the Hamad General Hospital
This will be a prospective randomized 2 year study of patients admitted to the Hamad General Hospital (HGH) and the Stroke Prevention Clinic with a diagnosis of ischemic stroke (IS) and Transit ischemic attacks (TIAs).
- Trial name
- PROMOTE-HEALTH (NCT02868723)
- Testing
- Aggressive Management
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke, Atrial Fibrillation
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below: 1.
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events
- Trial name
- BASE (NCT02014896)
- Testing
- Biomarker blood draw
- Where
- 22 sites in United States
- Volunteers
- 1,750 people
- Sponsor
- Ischemia Care LLC
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.
- Trial name
- OPAL-2 (NCT00938730)
- Testing
- YM150, Warfarin
- Where
- 170 sites in Australia, Austria and 21 more
- Volunteers
- 1,280 people
- Sponsor
- Astellas Pharma Inc
Acute Stroke, Transient Ischemic Attack
The Recurrence Study
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack (TIA) clinic.
- Trial name
- NCT03244215
- Testing
- Corneal Confocal Imaging, Magnetic resonance Imaging, Blood sample
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Ischemic Stroke, Transient Ischemic Attack
VISSIT Intracranial Stent Study for Ischemic Therapy
The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.
- Trial name
- VISSIT (NCT00816166)
- Testing
- Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel), Aspirin and Clopidogrel (Medical therapy)
- Volunteers
- 125 people
- Sponsor
- Codman & Shurtleff
Cerebral Stroke, Stroke, Acute
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
- Conditions
- Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
- Trial name
- NCT00061022
- Testing
- NXY-059
- Where
- 256 sites in United States, Argentina and 28 more
- Volunteers
- 3,200 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Stroke, Embolism
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous…
- Trial name
- NEURO-XAR (NCT01925755)
- Testing
- Rivaroxaban ( Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 209 people
- Sponsor
- Bayer
Cardiovascular Disease
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.
- Trial name
- SPARCL (NCT00147602)
- Testing
- atorvastatin
- Where
- 130 sites in Australia, Austria and 23 more
- Volunteers
- 4,732 people
- Sponsor
- Pfizer
MCA - Middle Cerebral Artery Dissection
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
- Trial name
- NCT02953405
- Testing
- Clopidogrel
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Thrombosis
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are…
- Trial name
- NCT02671461
- Testing
- BMS-986141, Aspirin
- Where
- 33 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Ischaemic Attack, Transient
Safety Escalating Repeat IV, in Stroke Patients
The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.
- Trial name
- MAG111539 (NCT00833989)
- Testing
- GSK249320
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Carotid Artery Disease, Stroke
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA)…
- Conditions
- Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
- Trial name
- CANOPY (NCT01445613)
- Testing
- RX Acculink Carotid Stent System (RX Acculink)
- Where
- United States
- Volunteers
- 1,203 people
- Sponsor
- Abbott Medical Devices